Reiner, Benjamin C.
Chehimi, Samar N.
Merkel, Riley
Toikumo, Sylvanus
Berrettini, Wade H.
Kranzler, Henry R.
Sanchez-Roige, Sandra
Kember, Rachel L.
Schmidt, Heath D.
Crist, Richard C.
Funding for this research was provided by:
National Institute on Drug Abuse (R21 DA057458, R21 DA055846, DP1 DA054394)
National Institute on Alcohol Abuse and Alcoholism (R01 AA030056)
Pennsylvania Department of Health (Nonformula Tobacco Settlement Act Grant)
U.S. Department of Veterans Affairs (I01 BX004820)
Tobacco-Related Disease Research Program (T32IR5226)
Article History
Received: 16 May 2024
Accepted: 2 August 2024
First Online: 6 August 2024
Competing interests
: B.C.R. receives research funding from Novo Nordisk and Boehringer Ingelheim that was not used in support of these studies. H.R.K. is a member of advisory boards for Dicerna Pharmaceuticals, Sophrosyne Pharmaceuticals, Enthion Pharmaceuticals, and Clearmind Medicine; a consultant to Sobrera Pharmaceuticals; the recipient of research funding and medication supplies for an investigator-initiated study from Alkermes; a member of the American Society of Clinical Psychopharmacology’s Alcohol Clinical Trials Initiative, which was supported in the last 3 years by Alkermes, Dicerna, Ethypharm, Lundbeck, Mitsubishi, Otsuka, and Pear Therapeutics; and a holder of U.S. patent 10,900,082 titled: “Genotype-guided dosing of opioid agonists”, issued 26 January 2021. All other authors declare no competing interests.